Clinical trials: Elevated Prostate Specific Antigen
Prostate Infections
Impact of Antibiotic Treatment on Prostate-Specific Antigen (PSA) Variability
Ciprofloxacin hydrochloride has been approved by the Food and Drug Administration (FDA) for the treatment of mild to moderate infections, including prostate infections.
- Trial name
- NCT00596453
- Testing
- Ciprofloxacin hydrochloride
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Johns Hopkins University
Prostatic Neoplasms
Early Rising PSA Endocrine Treatment Versus Chemo-endocrine Therapy- SPCG14
Summary In patients with prostate cancer (PC) who have only biochemically relapsed disease after curative treatment (or some locally advanced PC patients), hormonal therapy remains a de facto standard of care treatment.
- Trial name
- NCT03119857
- Testing
- Antiandrogen, Antiandrogen+docetaxel
- Where
- 5 sites in Denmark, Finland and 2 more
- Volunteers
- 349 people
- Sponsor
- Göteborg University
Prostate Cancer
Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC
The purpose of this trial is to learn more about the effects of AAA602 and AAA802 in men with prostate-specific membrane antigen (PSMA) positive high-risk localized prostate cancer (HRLPC) before surgery to remove the prostate…
- Trial name
- NeoPSMA (NCT06881823)
- Testing
- AAA602, AAA802, Gallium (68Ga) gozetotide
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens.
- Trial name
- NCT00003653
- Testing
- bicalutamide, buserelin, cyproterone acetate
- Where
- 29 sites in Canada
- Volunteers
- 1,386 people
- Sponsor
- NCIC Clinical Trials Group
Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer
Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer
This phase II trial studies selinexor in treating patients with prostate cancer that has spread to other parts of the body (metastatic), keeps growing even when the amount of testosterone in the body is reduced to very low levels…
- Conditions
- Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone
- Trial name
- NCT02215161
- Testing
- Selinexor
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of California, San Francisco
Prostate Cancer
Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC)
The primary objective of this study is to evaluate PSA response rates of the combination of Doxil and Thalidomide in patients with AIPC who have failed chemotherapy.
- Trial name
- NCT00307294
- Testing
- Thalidomide, Doxil
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Pittsburgh
Prostate Disease, Elevated Prostate Specific Antigen
MR/TRUS Fusion Guided Prostate Biopsy
This study will determine if targeted (Magnetic Resonance (MR) / Ultrasound (US) fusion biopsy) plus conventional biopsy is superior to conventional biopsy alone in diagnosing subjects with prostate cancer.
- Conditions
- Prostate Disease, Elevated Prostate Specific Antigen, Family History of Prostate Cancer, Positive Digital Rectal Exam
- Trial name
- NCT04026763
- Testing
- prostate biopsy, MR US Fusion Guided Prostate Biopsy, MR/TRUS Fusion Guided Prostate Biopsy
- Where
- United States
- Volunteers
- 520 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Elevated Prostate Specific Antigen
Randomized Trial of Ciprofloxacin Versus Observation for Men With Elevated Prostate Specific Antigen (PSA)
The purpose of this study is to assess the impact of an empiric course of antibiotics for men with an elevated prostate-specific antigen (PSA) level.
- Trial name
- NCT00840294
- Testing
- Ciprofloxacin
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- University of Chicago
Prostate Cancer
Targeted Prostate Biopsy Using a Novel MRI-Ultrasound Fusion Device
The purpose of this study is to evaluate the effectiveness of Focal-Fusion Bx at detecting clinically significant prostate cancer in a standard clinical environment.
- Trial name
- NCT02524860
- Testing
- Focal-Fusion Bx
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Focal Healthcare Inc.
PSA Progression, PSA
MRI-Assisted Guidance for Non-Essential Tissue Sampling
The study aims to determine if a less painful and less invasive prostate biopsy approach is safe for certain men with a high risk of prostate cancer.
- Trial name
- NCT07516223
- Testing
- Paired Prostate Biopsy Cohort (TB + SB)
- Where
- China
- Volunteers
- 1,235 people
- Sponsor
- Shanghai East Hospital
Prostatic Neoplasms
A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA)
The primary objective was to evaluate and compare the efficacy of androgen deprivation with or without docetaxel as determined by the median progression free survival (PFS) over the period of 18-month therapy and at least…
- Trial name
- Rising PSA (NCT00514917)
- Testing
- Docetaxel, Leuprolide, Bicalutamide
- Where
- 9 sites in United States, Belgium and 7 more
- Volunteers
- 413 people
- Sponsor
- Sanofi
Prostatic Neoplasms, Prostate Cancer
Study of Diagnostic Performance of [18F]CTT1057 in BCR
The current study aimed at evaluating the diagnostic performance of [18F]CTT1057 as a PET imaging agent for detection and localization of Prostate specific membrane antigen (PSMA) positivity in patients diagnosed of biochemical…
- Conditions
- Prostatic Neoplasms, Prostate Cancer, Recurrence
- Trial name
- GuidePath (NCT04838613)
- Testing
- [18F]CTT1057, [68Ga]Ga-PSMA-11
- Where
- 13 sites in United States, France and 2 more
- Volunteers
- 190 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)
This research study is comparing two different combinations of androgen deprivation therapy (ADT) used together with radiation as a treatment for rising PSA after radical prostatectomy (prostate cancer).
- Trial name
- NCT03141671
- Testing
- GnRH, Bicalutamide, Salvage radiation
- Where
- 8 sites in United States
- Volunteers
- 345 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer
Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer
This research is being done to evaluate the safety and efficacy of the investigational Kanglaite gelcap (KLTc) on PSA in men with prostate cancer when given for twelve months.
- Trial name
- NCT01483586
- Testing
- kanglaite gelcap
- Where
- 5 sites in United States
- Volunteers
- 90 people
- Sponsor
- KangLaiTe USA
Prostate Cancer
18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment
This prospective study will enroll up to 330 men with PSA-persistent or PSA-recurrent prostate cancer after curative-intent primary therapy and negative or equivocal findings on standard-of-care imaging.
- Trial name
- LOCATE (NCT02680041)
- Testing
- 18F-fluciclovine PET CT
- Where
- 17 sites in United States
- Volunteers
- 221 people
- Sponsor
- Blue Earth Diagnostics
Elevated Serum PSA
Impact of Anti-inflammatory Medications in Patients With Elevated Serum Prostate-specific Antigen
The purpose of this study is to assess the impact of ibuprofen in men with elevated serum PSA.
- Trial name
- NCT05512754
- Testing
- Ibuprofen 400 mg
- Where
- 3 sites in United States
- Volunteers
- 200 people
- Sponsor
- University of Chicago
Prostate-Specific Antigen
The Efficacy of Decision Support E-book for Prostate Biopsy Decision Making
PURPOSE: This study is to test the efficacy of decision support E-Book for 1) increasing prostate biopsy knowledge and decision self-efficacy, and 2) reducing decisional conflict on prostate biopsy decision making in patients…
- Trial name
- NCT03881709
- Testing
- Using an E-Book
- Where
- Taiwan
- Volunteers
- 110 people
- Sponsor
- National Taipei University of Nursing and Health Sciences
Prostatic Neoplasms
Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy
This clinical trial will evaluate the dosimetry, efficacy and toxicity of Lu-PSMA in men with high PSMA-expressing high-risk localized or locoregional advanced prostate cancer (HRCaP) undergoing radical prostatectomy (RP) and…
- Trial name
- LuTectomy (NCT04430192)
- Testing
- 177Lu-PSMA-617
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide
This research trial studies molecular features and pathways in predicting drug resistance in patients with castration-resistant prostate cancer that has spread to other parts of the body and who are receiving enzalutamide.
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, PSA Progression
- Trial name
- NCT02228265
- Testing
- Cytology Specimen Collection Procedure, Enzalutamide, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- OHSU Knight Cancer Institute
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
This randomized phase II trial studies the side effects and how well abiraterone acetate, prednisone, and apalutamide work with or without ipilimumab or cabazitaxel and carboplatin in treating patients with castration-resistant…
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, PSA Progression
- Trial name
- NCT02703623
- Testing
- Abiraterone Acetate, Apalutamide, Cabazitaxel
- Where
- 3 sites in United States
- Volunteers
- 196 people
- Sponsor
- M.D. Anderson Cancer Center